Mark Winderlich is the Chief Development Officer at HOOKIPA Pharma, bringing over 13 years of experience in clinical and preclinical drug development. They held various leadership roles at MorphoSys, including Vice President and Head of Biostatistics & Data Management, where they contributed to the FDA approval of Monjuvi (tafasitamab). Mark earned a PhD in biomedicine and an MSc in medical biometry, demonstrating a strong commitment to data-driven scientific excellence and team development. Currently, Mark is focused on advancing innovative drug development strategies to enhance patient outcomes.
This person is not in the org chart
This person is not in any teams
This person is not in any offices